{"id":45020,"date":"2024-04-25T08:00:00","date_gmt":"2024-04-25T06:00:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-ab-interim-report-q1-2024\/"},"modified":"2026-08-10T13:02:34","modified_gmt":"2026-08-10T11:02:34","slug":"stille-ab-interim-report-q1-2024","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-ab-interim-report-q1-2024\/","title":{"rendered":"Stille AB: Interim Report Q1 2024"},"content":{"rendered":"
\n

Stille AB (publ) today presents the report for the first quarter 2024.<\/strong><\/p>\n<\/div>\n

\n

Revenue amounted to 139.7 MSEK (72.4) with Fehling consolidated from January 1st and strong underlying growth from both business units. Total growth amounted to 92.9 percent, and organic growth to 10.0 percent.<\/p>\n

“I am pleased to note that our growth remains strong in the first quarter and that the integration of Fehling goes according to plan”<\/em>, says Torbjörn Sköld and comments on the recent acquisition, “We are very pleased with the deep knowledge, strong customer focus and the energy that our new colleagues are demonstrating to become part of Stille’s growth journey. During the quarter, we have worked and focused on realizing synergies within sales, product offering and R&D.”<\/em><\/p>\n

The gross profit amounted to 48.6 percent (42.4) and operating profit before one-time costs amounted to 27.0 MSEK (10.4).<\/p>\n

”A strong start to 2024 – our products deliver value to our customers which creates strong demand, growth and a good cashflow”, <\/em>concludes Stille’s CEO.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
MSEK<\/strong><\/td>\nJAN-MAR<\/strong>
<\/strong>2024<\/strong><\/td>\n		JAN-MAR<\/strong>
<\/strong>2023<\/strong><\/td>\n		APR-MAR<\/strong>
<\/strong>2023\/2024<\/strong><\/td>\n		JAN-DEC<\/strong>
<\/strong>2023<\/strong><\/td>\n<\/tr>\n
Revenue<\/td>\n139.7<\/td>\n72.4<\/td>\n362.2<\/td>\n294.9<\/td>\n<\/tr>\n
Gross Profit Margin, %<\/td>\n48.6<\/td>\n42.4<\/td>\n51.0<\/td>\n44.8<\/td>\n<\/tr>\n
EBITDA, before one-time costs<\/td>\n33.7<\/td>\n13.7<\/td>\n69.2<\/td>\n62.6<\/td>\n<\/tr>\n
EBITDA, before one-time costs, %<\/td>\n24.1<\/td>\n19.0<\/td>\n22.8<\/td>\n21.2<\/td>\n<\/tr>\n
EBITDA<\/td>\n17.0<\/td>\n10.4<\/td>\n65.9<\/td>\n59.3<\/td>\n<\/tr>\n
Operating Profit, before one-time costs<\/td>\n27.0<\/td>\n10.4<\/td>\n51.4<\/td>\n48.3<\/td>\n<\/tr>\n
Operating Profit, before one-time costs, %<\/td>\n19.3<\/td>\n14.4<\/td>\n17.9<\/td>\n16.4<\/td>\n<\/tr>\n
Operating Profit<\/td>\n10.3<\/td>\n7.1<\/td>\n48.1<\/td>\n45.0<\/td>\n<\/tr>\n
Operating Profit, %<\/td>\n7.4<\/td>\n9.8<\/td>\n12.8<\/td>\n15.2<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Torshälla, April 25th, 2024.<\/p>\n<\/div>\n

\n

This information is information that Stille is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-25 08:00 CEST.<\/em><\/p>\n<\/div>\n

\n

Contact Details<\/strong>
Torbjörn Sköld<\/strong>
CEO & President
+46 (0)70 316 63 91 | torbjorn.skold@stille.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Stille AB (publ) develops, manufactures and markets medical devices<\/strong> for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se<\/a>.<\/p>\n<\/div>\n

\n

Attachments<\/strong>
Interim Report Q1 2024 (Only in Swedish)<\/a><\/p>\n<\/div>\n